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A B S T R A C T
Background
Granulocyte colony stimulating factor (G-CSF) is a naturally-occurring cytokine that has been shown to increase neutrophil function
and number. Exogenous administration of recombinant G-CSF (filgrastim, pegfilgrastim or lenograstim) has found extensive use in
the treatment of febrile neutropaenia, but its role in the treatment of infection in non-neutropaenic hosts is less well defined.
Objectives
We aimed to explore the role of G-CSF as an adjunct to antibiotics in the treatment of pneumonia in non-neutropaenic adults.
Search strategy
A search was performed using the Cochrane Central Register of Controlled Trials (issue 1, 2003); MEDLINE (January 1966 to
April 2003); EMBASE (1988 to 2003); online databases of clinical trials; contact with corresponding authors; and contact with the
manufacturers and distributors of G-CSF and reviews of citations in publications identified by the above strategies.
Selection criteria
We considered randomised controlled trials (RCTs) which included hospitalised adult patients with either community acquired pneu-
monia or hospital-acquired pneumonia.
Data collection and analysis
Studies identified were reviewed independently by two reviewers with data abstracted onto standardized data collection forms. The
primary outcome measure was 28 day mortality. Secondary outcome measures included other markers of mortality as well as markers
of adverse events, including organ dysfunction. An assessment of methodological quality was made for each study.
Main results
G-CSF use appeared to be safe with no increase in the incidence of total serious adverse events (pooled OR 0.91, 95% CI: 0.73, 1.14)
or organ dysfunction. However, the use of G-CSF was not associated with improved 28 day mortality (pooled OR 0.99, 95% CI 0.77,
1.29).
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Reviewers’ conclusions
There is no current evidence supporting the routine use of G-CSF in the treatment of pneumonia. Studies in which G-CSF is
administered prophylactically or earlier in therapy may be of interest.
P L A I N L A N G U A G E S U M M A R Y
Synopsis
Granulocyte colony stimulating factor (G-CSF) does not reduce mortality in adults with pneumonia
Pneumonia, or infection involving the lungs, is responsible for a significant number of deaths worldwide. Pneumonia is especially
life-threatening in older people and people with other illnesses that may affect the immune system (such as diabetes). In addition to
antibiotics, granulocyte colony stimulating factor (G-CSF) has been suggested a possible option for treatment. G-CSF stimulates the
production of white blood cells that fight infection, and is used for people with cancer after chemotherapy. The review of trials found
that G-CSF appears to be a safe treatment for people with pneumonia, but it does not appear to reduce mortality. More research is
needed.
B A C K G R O U N D
This review explores the use of granulocyte-colony stimulating
factor (G-CSF) as an adjunct to antibiotics in the treatment of
pneumonia in non-neutropaenic adults. Much of the mortality
associated with pneumonia is related to sepsis, thought to repre-
sent a state of uncontrolled inflammation. Immunomodulation of
this response, using physiological doses of corticosteroids (Annane
2002) and recombinant activated protein C (Bernard 2001) have
been associated with improved outcomes. G-CSF, a naturally oc-
curring cytokine, may augment the neutrophil response to bacte-
rial infections.
Recombinant G-CSF has been shown to increase proliferation and
differentiation of neutrophil precursors. It has found widespread
use in reducing the duration of febrile neutropaenia following cy-
totoxic chemotherapy (Welte 1996), although its effect onmortal-
ity is questionable (Berghmans 2002). Other accepted indications
include neutropaenia following bone marrow transplantation, the
mobilization of peripheral blood progenitor cells in healthy donors
and in the treatment of severe congenital neutropaenia.
Its use in non-neutropaenic infection is based on three possible
mechanisms of action:
1. enhanced chemotaxis, superoxide production and killing activ-
ity (Hartung 1999);
2. immunomodulation of the cytokine response in sepsis (Weiss
1999);
3. a possible increase in intracellular uptake of antibiotics (
McKenna 1996).
However, a possible concern with its use in sepsis is the role of neu-
trophils in the development of organdysfunction, and inparticular
adult respiratory distress syndrome (ARDS). Increasing neutrophil
number and function may increase the risk of these adverse seque-
lae. A review of 84 cases of probable G-CSF related pulmonary
toxicity, mostly administered following chemotherapy, found that
G-CSF may increase the toxicity associated with cytotoxic agents
and infectious insults in neutropaenic patients (Azoulay 2001).
G-CSF has shown promise in the treatment of infection in non-
neutropaenic hosts in animal models (Hebert 1990; Smith 1995)
and in at least one case series with a historical control group
(Stephens 2002). It should be distinguished from GM-CSF (sar-
gramostim), which is used occasionally in stem cell mobilization
and to promote engraftment following bone marrow transplanta-
tion.
Community-acquired pneumonia is the leading cause of death
from infectious disease and results in approximately 600,000 ad-
missions per year in the United States (Bartlett 1995). Both
community-acquired pneumonia and hospital-acquired pneumo-
nia are associated with a significant mortality. (Fagon 1993a;
Niederman 1993). A number of trials of G-CSF in the treatment
of pneumonia have been performed. A review of these trials may
clarify the role of this immunomodulatory therapy and aid design
of future trials.
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O B J E C T I V E S
To assess the effectiveness and safety of G-CSF as an adjunct to
antibiotics for the treatment of pneumonia in non-neutropaenic
adults.
R E S U L T S
Mortality and other efficacy endpoints
None of the studies demonstrated a statistically significant mortal-
ity benefit; a pooled estimate of efficacy similarly did not demon-
strate a significant benefit associated with G-CSF. There was no
heterogeneity amongst studies with regard to 28 day mortality (p
= 0.14). Pooling results across all four studies, the pooled odds
ratio for 28 day mortality was 0.99 (fixed effects model; 95% con-
fidence interval (CI): 0.77, 1.29).
A number of the endpoints intended for analysis were not re-
ported, including time to hospital discharge (no interquartile
range reported in any study), the rate of intubation (only re-
ported in Nelson 1998), in-hospital mortality (only reported in
Nelson 1998). Duration of ICU stay was not reported in one study
(Wunderink 2001).
Adverse events
Overall, there was a reduction in adverse events that was not sta-
tistically significant (pooled odds ratio was 0.91; 95% CI: 0.73,
1.14). This was largely due to a reduction in rates in organ dys-
function, highest in the study of community-acquired pneumonia
(Nelson 1998). In that study, there was a significant decrease in
rates of ARDS (OR 0.28; 95%CI: 0.09, 0.28) but this was not
seen in subsequent studies.
Community acquired pneumonia, hospital acquired pneumo-
nia and ventilator-associated pneumonia
Only one of the two studies that included patients with hospital-
acquired pneumonia reported results by category. In the larger
study (Root 2003), patients with hospital-acquired pneumonia
constituted a minority (20%) of patients and were distributed
evenly in intervention and placebo groups.
Presence of severe sepsis
Outcome measures were not reported by the presence or absence
of severe sepsis in the earlier trials. (Nelson 1998; Nelson 2000).
In these trials, however, septic shock was a specific exclusion; the
pooled odds ratio of incident septic shock was 0.60 (95%CI: 0.34,
1.08). There was a moderate decrease in 28 day mortality in these
trials (pooled OR 0.80; 95%CI: 0.52, 1.22) that was not statisti-
cally significant.
There was a trend to an increasing odds ratio of serious adverse
events and organ dysfunction in the studies of patients with se-
vere sepsis in filgrastim-treated patients (Wunderink 2001; Root
2003). For total serious adverse events, the pooled odds ratio in
the studies of patients with severe sepsis was 1.10 (95%CI 0.82,
1.49) compared to the other studies (0.72 (0.51, 1.01).
Bacterial aetiology
Results were not reported by bacterial aetiology; it was not possible
to draw conclusions on the efficacy of G-CSF in each of these
groups.
Analyses of patients with specific co-morbidities
We were also unable to perform subgroup analyses on patients
with specific co-morbid conditions due to a lack of data.
Sensitivity analysis
Given the small number of studies, all of good quality, no sensi-
tivity analysis was performed.
Assessment of publication bias
No individual study demonstrated a mortality benefit. The ability
to interpret a funnel plot was limited by the small number of trials
identified.
D I S C U S S I O N
Efficacy
This analysis suggests that there is no clinically significant bene-
fit associated with the use of G-CSF. Richard Root (Root 2003)
suggests several reasons for the failure of previous animal work
to demonstrate results in humans; invalid hypothesis, inadequate
dosing or activity, improper study design or failed execution. He
suggests that, primarily, delays in the administration of G-CSF to
satisfy microbiological study criteria may have contributed to its
negative result.
We performed this review in preparation for a trial of G-CSF in
Burkholderiapseudomallei (B. pseudomallei) pneumonia where we
wished to determine if G-CSF may benefit patients with acquired
neutrophil dysfunction due to co-morbid conditions such as dia-
betes, alcohol and renal failure, or with infections due to intracel-
lular organisms such as B. pseudomallei. However, we have been
unable to answer this question specifically from the data available.
Adverse events
Our results suggest that G-CSF does not increase the rates of im-
munologically mediated organ dysfunction by a clinically signifi-
cant extent. A theoretical concern has been that the use of G-CSF
may increase the rate of immunologicallymediated end-organ dys-
function, such as the adult respiratory distress syndrome (ARDS),
to which patients with severe sepsis are particularly prone.
There was a trend towards an increasing risk of organ dysfunction
in patients more severely unwell and treated with G-CSF, suggest-
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ing that this may have been due to an exacerbation of immuno-
logically mediated disease in patients more at risk of developing
organ dysfunction. However, this was not statistically significant
in any study and remains speculative. The trend towards a reduc-
tion in incident septic shock in patients without this complication
at study enrolment may suggest that G-CSF may be operating to
prevent this complication.
Decision to pool data from trials
Despite the clinical heterogeneity present between the study pop-
ulations, we felt it appropriate to pool the results to obtain an
overall estimate of efficacy. It was felt that although the inclusion
criteria were different, these patients all had varying severity of the
same disease and thus the relative efficacy might be expected to
remain the same in each group, although the absolute benefit (or
harm) might be expected to vary with the mortality of the pop-
ulation studied. Similarly, it was felt that, although patients with
severe sepsis may be a higher risk of developing this complication,
the mechanism of end-organ dysfunction was the same.
Possible sources of bias
We felt that given the lack of effect demonstrated by the individ-
ual published trials, a significant publication bias is unlikely to be
operating. However, it is possible that trials may have been with-
held from publication due to harmful effects. We have no specific
information suggesting this possibility.
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